← Leaderboards
Natalia Issaeva
Univ Of North Carolina Chapel Hill
$2,582,417
Attributed
$7,389,433
Total exposure
3
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2019–25$2M$1.5M$1M$500K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,389,433 · 3
By mechanism
U01$3,752,383 · 1
R01$3,637,050 · 2
Top collaborators
- Wendell G Yarbrough13 shared
- Karen S Anderson5 shared
- Daniel Ma3 shared
- Kathryn Van Abel3 shared
- Bhisham Chera1 shared
- Gaorav P. Gupta1 shared
Most similar at Univ Of North Carolina Chapel Hill
Same institution · by research overlap
- David N Hayes$17,915,459
- Carla J Chibwesha$4,372,568
- Travis P. Schrank$869,965
- Joseph David Tucker$13,115,535
- Cary A Moody$8,050,523
Others in their field
Other Emerging Leaders on “Side Effect”
- Jeffrey Reich · Sparian Biosciences, Inc.$13,729,307
- Jacob D Estes · Oregon Health & Science University$9,581,486
- James N Campbell · Centrexion Therapeutics Corporation$8,662,635
- Gary Fanger · Rise Therapeutics, Llc$8,225,136
- Katherine Teresa Mills · Tulane University Of Louisiana$7,657,098
- Warren David Lo · Virginia Polytechnic Inst And St Univ$7,249,509
Research focus
Side EffectCharacteristicsPrognostic MarkerRadiationRecurrenceTumorNovel TherapeuticsGenesCervical And Uterine CancerClinical TrialsHuman PapillomavirusAftercareUnited StatesPreventOncogenicDetectionLeadDiagnosisMalignant NeoplasmsOropharyngeal Squamous Cell CarcinomaOperative Surgical ProceduresEnrollmentChemotherapyHead And Neck Structure
Grant awards (13)
Dissecting NF-kB pathway in HPV-associated head and neck cancer$509,676
R01 · FY2025 · DE
Observational study to validate circulating HPVDNA and prognostic genomic biomarkers for diagnosis and treatment of HPV-associated OPSCC$704,533
U01 · FY2024 · DE
Dissecting NF-kB pathway in HPV-associated head and neck cancer$536,605
R01 · FY2024 · DE
Observational study to validate circulating HPVDNA and prognostic genomic biomarkers for diagnosis and treatment of HPV-associated OPSCC$735,619
U01 · FY2023 · DE
Dissecting NF-kB pathway in HPV-associated head and neck cancer$488,746
R01 · FY2023 · DE
Exploring mechanisms of therapeutic demethylation effects in HPV-associated head and neck cancer$404,678
R01 · FY2023 · DE
Observational study to validate circulating HPVDNA and prognostic genomic biomarkers for diagnosis and treatment of HPV-associated OPSCC$741,313
U01 · FY2022 · DE
Exploring mechanisms of therapeutic demethylation effects in HPV-associated head and neck cancer$400,632
R01 · FY2022 · DE
Observational study to validate circulating HPVDNA and prognostic genomic biomarkers for diagnosis and treatment of HPV-associated OPSCC$761,468
U01 · FY2021 · DE
Exploring mechanisms of therapeutic demethylation effects in HPV-associated head and neck cancer$404,678
R01 · FY2021 · DE
Observational study to validate circulating HPVDNA and prognostic genomic biomarkers for diagnosis and treatment of HPV-associated OPSCC$809,450
U01 · FY2020 · DE
Exploring mechanisms of therapeutic demethylation effects in HPV-associated head and neck cancer$404,678
R01 · FY2020 · DE
Exploring mechanisms of therapeutic demethylation effects in HPV-associated head and neck cancer$487,357
R01 · FY2019 · DE